TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01426529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippuric Acid
Description: Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippuric Acid
Description: Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A hormone that is normally present in your body, which regulates your blood pressure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Study: NCT04056468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.
Study: NCT04513509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin
Description: Start with empirical lower dose for 3 months, and then titrate up
Study: NCT01883674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
Study: NCT03210532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan + Amlodipine + Rosuvastatin
Description: Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan + Amlodipine
Description: Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan + Rosuvastatin
Description: Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
Study: NCT01680614

Intervention type: BEHAVIORAL
Intervention: CASI
Study: NCT02141555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol
Description: Misoprostol inserted into vagina

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Misoprostol
Description: Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
Study: NCT02641834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian diet
Description: 7-days dietary profile with an isocaloric Vegetarian diet for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: 7-days dietary profile with an isocaloric Vegetarian diet for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: 7-days dietary profile with an isocaloric Mediterranean diet for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: 7-days dietary profile with an isocaloric Mediterranean diet for 3 months
Study: NCT02312843

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise/Aerobic

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise/Stretching
Study: NCT03365648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lertal® + standard therapy
Description: Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~* Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~* Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~* Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + standard therapy
Description: Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine
Study: NCT04547751

Intervention type: OTHER
Intervention: targeted high-resolution mass spectrometry
Description: difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry

Intervention type: OTHER
Intervention: targeted high-resolution mass spectrometry
Description: difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry
Study: NCT01991795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg bd taken orally as tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor placebo
Description: Ticagrelor placebo bd taken orally as tablets
Study: NCT00769769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
Study: NCT01721902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous CD133+ Bone Marrow Stem Cells
Description: Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carrier Solution
Description: Intra-myocardial injection of carrier solution
Study: NCT03076879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting participation in cervical cancer screening
Description: Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training.
Study: NCT05372159

Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study

Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study
Study: NCT01613833

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood drawn for A2M levels to be assayed at Cytonics

Intervention type: PROCEDURE
Intervention: Joint Aspirate Harvest
Description: Joint aspirate harvested for A2M levels to be assayed at Cytonics

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood drawn for A2M levels to be assayed at Cytonics

Intervention type: PROCEDURE
Intervention: Joint Aspirate Harvest
Description: Joint aspirate harvested for A2M levels to be assayed at Cytonics
Study: NCT01413802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous nerve monitoring
Description: Continuous nerve monitoring is performed during thyroid surgery.
Study: NCT03012737

Intervention type: DEVICE
Group type: OTHER
Intervention: Trilogy 100 ® (Philips Respironics)
Description: Trilogy 100 ® (Philips Respironics) on MPV mode.
Study: NCT03980223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate Delayed-Release 200 mg
Description: 200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
Study: NCT04043026

Intervention type: DRUG
Intervention: Statin
Description: Any statin therapy
Study: NCT03229499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: matching placebo tablet
Study: NCT01214278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rTG
Description: EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GArTG
Description: EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE
Description: EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL
Description: DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
Study: NCT01471626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polysomnograph Dream and Sleep Box
Description: Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
Study: NCT02920658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAVS Naphthalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Betamethasone dipropionate
Study: NCT02425085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-endodiathermy retinectomy
Description: patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: relaxing retinectomy
Description: patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
Study: NCT00127803

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vaccine diluent)
Description: 0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: 0.5 mL, intramuscular on Days 0, 28, and 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: 0.5 mL, intramuscular on Days 0, 28, and 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: 0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
Study: NCT04812158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard ankle physiotherapy or rehabilitation for chronic ankle instability
Description: 6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard ankle physiotherapy or rehabilitation for chronic ankle instability
Description: 6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
Study: NCT01180062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2
Description: Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost SR insert
Description: Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
Study: NCT01211171

Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT02478827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
Study: NCT03169439

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Irreversible electroporation
Description: minimal invasive ablative technique for tumors
Study: NCT02640209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART 19
Description: The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
Study: NCT02715453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention on frailty
Description: Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~* Nutritional evaluation and intervention after randomization and regularly during follow-up~* Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~* Psychiatrist or psychologist assistance for 1 year after discharge
Study: NCT03755817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENAR application
Description: Active SCENAR application on the painful area

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SCENAR application with the device off
Description: Placebo SCENAR application on the painful area
Study: NCT04179643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10e13vg NAN-101
Description: There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10e13vg NAN-101
Description: There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10e13vg NAN-101
Description: There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
Study: NCT01544231

Intervention type: BIOLOGICAL
Intervention: Plasma NGAL level
Description: The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
Study: NCT01154660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal Volume
Description: observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal Volume
Description: observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
Study: NCT01918228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talks about what science says about LBP
Description: Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
Study: NCT01550926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 mg orlistat
Description: 2 X60 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg orlistat
Description: 60 mg orlistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat experimental dose
Description: experimental
Study: NCT03982537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl-L-Cysteine dietary supplement
Description: Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy and Radiation
Description: Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.

Intervention type: RADIATION
Group type: OTHER
Intervention: Chemotherapy and Radiation
Description: Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
Study: NCT04131972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REGENERA
Description: REGENERA breast implant
Study: NCT03721354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA vs PSV - TCCD
Description: Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker.
Study: NCT02239289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Idem as described in the arm section (above)
Study: NCT02542527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid filled breast pump
Description: breast milk pumping with a fluid filled breast pump
Study: NCT02057341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule
Study: NCT00862992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 12.5 mg